AMX vs TTWO

AMX exhibits mixed financial health with a Piotroski F-Score of 4/9 indicating borderline stability, while the absence of an Altman Z-Score prevents a full distress risk assessment. The stock appears reasonably valued with a current price of $20.76 below the growth-based intrinsic value of $37.76, though significantly above the conservative Graham Number of $3.26. Strong operating margins and ROE outperform sector averages, but weak earnings consistency, high debt/equity, and deteriorating short-term technical trend temper optimism. Analysts recommend a 'buy' with a $23.40 target, implying moderate upside.

The deterministic health profile is weak, highlighted by a Piotroski F-Score of 2/9, indicating significant operational and financial instability. While the company exhibits strong top-line revenue growth of 24.9% and maintains a 'strong_buy' analyst consensus with a target price of $276.74, these are countered by a severe profit margin of -60.45% and bearish insider activity. The stock is currently trading as a growth play on future catalysts rather than current fundamentals, as evidenced by the high Price/Book ratio of 11.48 and a lack of positive earnings consistency.